BioSpace News Archive

Nass Valley Gateway Ltd. (the “Nass Valley” or “Company”), listed on the Canadian Securities Exchange (“CSE”) under the trading Symbol “NVG” and on Deutsche Boerse Frankfurt under the trading Symbol 3NVN, is pleased to announce that after providing the necessary documentations for its announced fundamental change to the satisfaction of the CSE, its shares will resume trading on March 29, 2019.

BLA submission to U.S. FDA for [fam-] trastuzumab deruxtecan in HER2 positive metastatic breast cancer previously treated with T-DM1 to be accelerated to first half of fiscal year 2019

Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates; AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia

KLAS interviewed customers from active healthcare command center vendors to gather insights into the underutilized approach of using Operational Command Centers.

Agreement will Enable Transcenta to Develop Novel Biotherapeutics for Bone Diseases in China

Blueprint Medicines Corporation announced the pricing of an underwritten public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share, before underwriting discounts and commissions.

Full year revenue grew 74% to US$69.5M with 30% Adjusted EBITDA and US$0.14 EPS

JIUN Corporation started providing its cloud-based medical image management system “SonicDICOM PACS Cloud Beta” on March 28, 2019.

Luye Pharma Group has announced submission of a new drug application to the U.S. Food and Drug Administration for Rykindo®, completed on March 28.

New cost competitive wafer-to-wafer layer transfer process delivers low power, increased yield and higher interconnection density and speed